The main goal of the present study was to determine whether there was any difference between the effects of two lipid lowering drugs, fenofibrate and atorvastatin, on plasma homocysteine concentration and folic acid and vitamin B12 levels which are main factors involving homocysteine metabolism. The efficiacy of both agents in lowering lipid levels has been proven in large clinical trials
19-22. Recently it was shown that treatment with fibrates increases plasma homocysteine concentration
15-17. In accordance with these observations, present findings also demonstrate that homocysteine levels increase after fenofibrate treatment. In addition, we have also found that treatment with atorvastatin results a moderate increase in plasma homocysteine levels in hyperlipidemic patients. The increase was higher in fenofibrate group than in atorvastatin group (36 vs. 15%, p<0.01). In contrast to the present result, Giral et al.
19 have shown that treatment with atorvastatin did not exert any significant effect on the plasma homocysteine levels.
One study reported that fenofibrate dramatically increases plasma homocysteine levels, though blood levels of vitamins were not reduced and they proposed that it may be related to the renal function 15. In the present study we also did not detect any change in vitamin B12 and folic acid concentration after treatment with both lipid lowering agents. The increase in homocysteine levels were not related with these vitamin levels. In addition Lipscombe et al. 23 reported that a group of patients showed a reversible deterioration in renal function while being treated with a fibrate for hyperlipidemia. The possible explanation for the fenofibrate-induced increase in homocysteine levels may involve alteration in renal function. Indeed, in the present study uric acid and creatinin levels increased by the treatment with fenofibrate as reported previously 24. On the other hand, atorvastatin treatment did not show any significant effects on the concentration of uric acid and creatinin.
We have found a mild but significant increase in homocysteine levels after treatment with atorvastatin for 3 months but not 1 month. There are a few studies concerning atorvastatin and homocysteine. Giral et al.19 reported that atorvastatin has no effect on plasma homocysteine levels. The increase in homocysteine levels was not related kidney function in the present study because uric acid, creatinin and albumin levels did not show any significant change after atorvastatin treatment. On the other hand, present findings show another important result which is the changes in ALT, AST and amylase levels with the treatment of atorvastatin but not of fenofibrate. Liver has a significant role in the regulation of plasma homocysteine levels 25 with the help of the essential vitamins, including folic acid and vitamin B12, the liver converts homocysteine back into methionine. Impaired liver function could be a determinant in the development of hyperhomocysteinemia 26.
In conclusion, elevated homocysteine levels are a risk factor for atherosclerosis. Plasma homocysteine levels increased in the hyperlipidemic patients while treating another cardiovascular risk factor, hyperlipidemia, both with atorvastatin and fenofibrate. The significant elevation by fenofibrate may be due to its side effect on renal function. On the other hand, atorvastatin lead to a mild increase in plasma homocysteine levels and it may be explained by its effect on liver function.